Evercore ISI analyst Vijay Kumar upgraded Novocure to In Line from Underperform with an unchanged price target of $33. The firm says “nothing incremental here for us,” noting that it is moving to the sidelines now that the stock has hit its price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVCR:
- Novocure price target lowered to $102 from $104 at Wells Fargo
- NovoCure trading resumes
- NovoCure trading halted, volatility trading pause
- Novocure reports Q2 EPS (54c), consensus (50c)
- NovoCure put volume heavy and directionally bearish
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue